In comparison with the research focusing on the Keap1 inhibitors (i.e., Keap1-NRF2 disruptors/NRF2activators) and NRF2 agonists/activators, the research area of NRF2 antagonists/inhibitors for cancer treatment lags behind with very limited publications, especially concerning RCC. The gene discussed is KEAP1; the disease is renal cell carcinoma.